← back to search

Patrick Schloemer

Harvard University · US
Area of research
Endocrinology, Diabetes and Metabolism · Cardiology and Cardiovascular Medicine
Research interest
Research interests include Hormonal Regulation and Hypertension, Heart Failure Treatment and Management, Diabetes Treatment and Management, and Chronic Kidney Disease and Diabetes.
h-index
14
citations
3,620
works
66
NIH funding
primary concept
Medicine
email

Recent publications

Finerenone in Type 1 Diabetes and Chronic Kidney Disease
New England Journal of Medicine 2026cited by 5position: middledoi
Finerenone Reduces New-Onset Atrial Fibrillation Across the Spectrum of Cardio-Kidney-Metabolic Syndrome
Journal of the American College of Cardiology 2025cited by 24position: middledoi
Initial Decline in Glomerular Filtration Rate With Finerenone in HFmrEF/HFpEF
Journal of the American College of Cardiology 2025cited by 20position: middledoi
Finerenone and new-onset diabetes in heart failure: a prespecified analysis of the FINEARTS-HF trial
The Lancet Diabetes & Endocrinology 2025cited by 17position: middledoi
The Efficacy of Finerenone on Hierarchical Composite Endpoint Analysed Using Win Statistics in Patients with Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of FINEARTS-HF
European Journal of Heart Failure 2025cited by 9position: middledoi
Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes
Nature Medicine 2024cited by 114position: middledoi
Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial
Nephrology Dialysis Transplantation 2024cited by 69position: middledoi
Finerenone and Kidney Outcomes in Patients With Heart Failure
Journal of the American College of Cardiology 2024cited by 64position: middledoi
Development and Validation of a New Hierarchical Composite End Point for Clinical Trials of Kidney Disease Progression
Journal of the American Society of Nephrology 2023cited by 35position: middledoi
Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials
Kidney International 2023cited by 20position: middledoi
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
New England Journal of Medicine 2020cited by 2,581position: middledoi
Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes
Circulation 2020cited by 274position: middledoi
Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial
American Journal of Nephrology 2019cited by 177position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Muthiah Vaduganathan · Harvard University7 papers (2023–2025)Bertram Pitt · Bayer (Germany)7 papers (2019–2025) · 6 papers (2023–2025)Scott D. Solomon · Harvard University6 papers (2024–2025)Brian Claggett · Harvard University6 papers (2024–2025)Pardeep S. Jhund · Harvard University6 papers (2024–2025)John J.V. McMurray · University of Glasgow6 papers (2024–2025)Alasdair D Henderson · University of London6 papers (2024–2025)Peter Kolkhof · Bayer (United States)5 papers (2019–2025)Peter Rossing · University of Glasgow5 papers (2020–2026)Stefan D. Anker · Deutsches Herzzentrum München5 papers (2019–2025)Faı̈ez Zannad · Université de Caen Normandie5 papers (2024–2025)Luís M. Ruilope · Harvard University5 papers (2019–2025)Michele Senni · Ospedale Papa Giovanni XXIII4 papers (2024–2025)Akshay S. Desai · Twitter (United States)4 papers (2024–2025)Prabhakar Viswanathan · Bayer (United States)4 papers (2024–2025)Carolyn S.P. Lam · Duke-NUS Medical School3 papers (2024–2025)Adriaan A. Voors · Centre Hospitalier Régional et Universitaire de Nancy3 papers (2024–2025)Sanjiv J. Shah · Akron General Medical Center3 papers (2024–2025)George L. Bakris · University of Mississippi3 papers (2020–2023)